Impact of Timing the Combination of Radiotherapy and PD-1 Inhibitors on Outcomes in Patients with Hepatocellular Carcinoma
Liting Zhong,1,2,* Weiwei Peng,1,2,* Jingyuan Sun,3 Yongyi Luo,3 Hailong Sheng,4 Yi Wu,5 Tonggang Zhou,5 Chaoming Zhou,1,2 Chuanhui Cao1,3 1Department of Oncology, Ganzhou Hospital-Nanfang Hospital, Southern Medical University, Ganzhou, Jiangxi, People’s Republic of China; 2Departmen...
Saved in:
Main Authors: | Zhong L, Peng W, Sun J, Luo Y, Sheng H, Wu Y, Zhou T, Zhou C, Cao C |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2025-01-01
|
Series: | Journal of Hepatocellular Carcinoma |
Subjects: | |
Online Access: | https://www.dovepress.com/impact-of-timing-the-combination-of-radiotherapy-and-pd-1-inhibitors-o-peer-reviewed-fulltext-article-JHC |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Spatial heterogeneity of the hepatocellular carcinoma microenvironment determines the efficacy of immunotherapy
by: Minni Zhang, et al.
Published: (2025-01-01) -
Analysis of the risk of oncological adverse events associated with infliximab in combination with azathioprine compared to monotherapy: insights from the FAERS database
by: Qian Qiao, et al.
Published: (2025-01-01) -
PARP inhibitors as therapy for small cell lung carcinoma: A systematic review and meta-analysis of clinical trials
by: Samuel Pratama, et al.
Published: (2024-01-01) -
ALKBH5 acts a tumor-suppressive biomarker and is associated with immunotherapy response in hepatocellular carcinoma
by: Hehua Ma, et al.
Published: (2025-01-01) -
Immune-related adverse events with PD-1/PD-L1 inhibitors: insights from a real-world cohort of 2523 patients
by: Ting Yan, et al.
Published: (2025-01-01)